Efficacy and safety profile of GreenLight laser photoselective vaporization of the prostate in ≥ 75 years old patients: results from the Italian GreenLight Laser Study Group

Campobasso, Davide; Morselli, Simone; Greco, Francesco; Nunzio, Cosimo De; Destefanis, Paolo; Fasolis, Giuseppe; Varvello, Francesco; Voce, S.; Reale, Giulio; Cai, Tommaso; Oriti, Rino; Tuccio, Agostino; Ruggera, Lorenzo; Laganà, Antonino; Dadone, C.; Rienzo, Gaetano De; Pucci, Luigi; Carrino, Maurizio; Montefiore, F.; Rabito, Salvatore; Miano, Roberto; Schips, Luigi; Frattini, Antonio; Micali, Salvatore; Ferrari, Giovanni; Cindolo, Luca

doi:10.1007/s40520-023-02351-9

Cited by 6 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After removing duplicates, 292 records were screened for eligibility based on title and abstract, of which 61 records were selected for full‐text review. Thirty‐two articles 10–41 were included in the systematic review, of which four evaluated PAE, 10,28,38,40 four evaluated Rezum, 22,29,36,41 eight evaluated GreenLight, 13,15,19,24,26,27,31,35 seven evaluated HoLEP, 11,20,23,25,30,32,37 four evaluated thulium laser enucleation of the prostate (ThuLEP), 14,16–18 two evaluated diode laser enucleation of the prostate (DiLEP), 34,39 one evaluated Aquablation, 33 one evaluated both PAE and Rezum, 12 and one evaluated both GreenLight and HoLEP 21 (Figure 1).…”

Section: Resultsmentioning

confidence: 99%

“…A total of 3972 geriatric men from 32 studies 10–41 underwent a MIST for LUTS secondary to BPH. In terms of study design, 65.6% of studies 10,12–17,19–22,25,26,29–31,33,35,37,40,41 were retrospective in nature while the remaining studies 11,18,23,24,27,28,32,34,36,38,39 were prospective. The studies were conducted across the globe, seven of which were multicenter studies 12,15–17,19,29,33 .…”

Section: Resultsmentioning

confidence: 99%

“…In terms of study design, 65.6% of studies 10,12–17,19–22,25,26,29–31,33,35,37,40,41 were retrospective in nature while the remaining studies 11,18,23,24,27,28,32,34,36,38,39 were prospective. The studies were conducted across the globe, seven of which were multicenter studies 12,15–17,19,29,33 . One study 31 evaluating GreenLight and three studies 30,32,37 evaluating HoLEP included two subgroups of patients based on age (70–79 years and ≥80 years).…”

Section: Resultsmentioning

confidence: 99%

“…The studies were conducted across the globe, seven of which were multicenter studies. 12,[15][16][17]19,29,33 One study 31 evaluating GreenLight and three studies 30,32,37 evaluating HoLEP included two subgroups of patients based on age (70-79 years and ≥80 years).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…PAE, GreenLight, HoLEP, ThuLEP, DiLEP, and Aquablation required a planned overnight stay in all the studies, [10][11][12][13][14][15][16][17][18][19][20][21][23][24][25][26][27][28][30][31][32][33][34][35][37][38][39][40] while…”

Section: Mists Procedural Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

Minimally invasive surgical therapies for benign prostatic hyperplasia in the geriatric population: A systematic review

Abid,

Piperdi,

Babar

et al. 2024

The Prostate

View full text Add to dashboard Cite

BackgroundGeriatric patients, prone to adverse events (AEs) and low compliance with drugs, may benefit from minimally invasive surgical therapies (MISTs) for managing benign prostatic hyperplasia (BPH). We evaluated the efficacy, safety, and procedural characteristics of MISTs in geriatric patients with BPH.MethodsPubMed/MEDLINE database was systematically searched for relevant articles through October 1, 2023. Eligible studies focused on geriatric patients (≥65 years) with BPH who were treated with MISTs and evaluated follow‐up surgical, micturition, and/or sexual outcomes. Studies were included if there was separate reporting for age subgroups ≥65 years, or if the mean age minus standard deviation was ≥65 years, or if the first quartile was ≥65 years.ResultsOut of 292 screened studies, 32 (N = 3972 patients) met inclusion criteria and assessed prostatic artery embolization (PAE), Rezum, GreenLight, holmium laser enucleation of the prostate (HoLEP), thulium laser enucleation of the prostate (ThuLEP), diode laser enucleation of the prostate (DiLEP), and Aquablation. Except for Rezum, all MISTs required a planned overnight stay. While PAE and Rezum could be performed under local anesthesia, the other MISTs needed general or spinal anesthesia. Postoperative catheterization duration was longest for PAE (median 14 days) and Rezum (21 days) and shortest for GreenLight (1.9 days). At 12 months postoperatively, all MISTs exhibited significant percent changes in International Prostate Symptom Score (median −69.9%) and quality of life (median −72.5%). Clavien‐Dindo Grade 1 AEs ranged widely, with PAE (5.8%–36.8%), Rezum (0%–62.1%), and GreenLight (0%–67.6%) having the largest range, and HoLEP (0%–9.5%), ThuLEP (2%–6.9%), and DiLEP (5%–17.5%) having the smallest. PAE, Rezum, DiLEP, and Aquablation reported no significant changes in the International Index of Erectile Function.ConclusionsAlthough all the MISTs reviewed in this study effectively treat BPH in geriatric patients, differences in procedural characteristics and safety profiles across MISTs were considerable. Physicians should use shared decision‐making processes, considering risks and patient characteristics, when choosing a suitable treatment option for their patients.

show abstract